Home > Insider Trading > Filing (0000899243-21-021571)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1845337	Day One Biopharmaceuticals Inc.	DAWN	()	E9

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1712417	L.p. Xi Canaan	285 Riverside Avenue, Suite 250 Westport CT 06880		No	No	Yes	No
1850694	Canaan Partners Xi Llc	285 Riverside Avenue, Suite 250 Westport CT 06880		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-01	7,328,497	$0.00	10,574,366	No	4	C	Direct
Common Stock	Acquisiton	2021-06-01	148,279	$0.00	10,722,645	No	4	C	Direct
Common Stock	Acquisiton	2021-06-01	13,000	$16.00	10,735,645	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-06-01	7,328,497	$0.00	7,328,497	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-06-01	148,279	$0.00	148,279	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration.
These shares are held directly by Canaan XI L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners XI LLC ("Canaan XI", and together with the Canaan Fund, the "Canaan Entities"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively. Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration.